Market Research Report
North America Antihypertensive Drugs Market 2019-2028
|Published by||Inkwood Research||Product code||943441|
|Published||Content info||129 Pages
Delivery time: 2-3 business days
|North America Antihypertensive Drugs Market 2019-2028|
|Published: June 21, 2020||Content info: 129 Pages||
The North America antihypertensive drugs market is predicted to record a CAGR of 3.28% during the forecast period, 2019 to 2028. The growth rate is attributed to factors such as the surge in the predominance of hypertension and persistent kidney disorders. Moreover, prominent players like Johnson & Johnson and Merck & Co., Inc. promote market growth in this region.
The evaluation of the North America antihypertensive drugs market growth involves the market analysis of Canada and the United States. Canada's clinical practice regulations for the management of hypertension are in accordance with the Hypertension Canada Guidelines. They are developed by an expert volunteer network and are meticulously reviewed and regularly updated to keep healthcare professionals notified about hypertension management. According to statistics, the expenses designated to hypertension in Canada were estimated at more than $13 billion, and are expected to considerably increase over the years. Moreover, Canada's increased rates of awareness, medication, and management are instituted due to the combined efforts established by health care professionals and organizations. This is done in view of decreasing the weight of hypertension and efficient knowledge interpretation regarding hypertension and its subsequent risks. Therefore, these factors significantly contribute to driving the antihypertensive drugs market in Canada.
Merck & Co Inc, Johnson & Johnson, Lupin Limited, Novartis AG, Hill-Rom Holdings Inc, Sun Pharmaceutical Industries Ltd (Ranbaxy Laboratories), are some of the distinguished companies operating in the market.
Our report offerings include: